Quick Summary:
In an exponentially expanding healthcare sector, the global market for Lymphoma Therapeutics is poised for impressive growth. With an estimated valuation of US$14.9 Billion in the year 2022, it is projected to reach a staggering US$25.2 Billion by 2030. This comprehensive market research report will provide you with invaluable insights, including a deep dive into the segments such as Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL), and the post pandemic recovery trend.
Beyond this, the report offers crucial information about significant markets such as the U.S, estimated at $4.1 Billion, and China, forecast to grow at a striking 10.9% CAGR by 2030. It doesn't stop there; obtain detailed analysis of emerging markets, key competitors including giants like Amgen, Inc. and Pfizer, Inc., and the latest industry trends. Stay a step ahead in this competitive landscape with our meticulously crafted, data-driven report.
Global Lymphoma Therapeutics Market to Reach $25.2 Billion by 2030
The global market for Lymphoma Therapeutics estimated at US$14.9 Billion in the year 2022, is projected to reach a revised size of US$25.2 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2022-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$20.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hodgkin Lymphoma (HL) segment is readjusted to a revised 7.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4.1 Billion, While China is Forecast to Grow at 10.9% CAGR
The Lymphoma Therapeutics market in the U.S. is estimated at US$4.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.Select Competitors (Total 93 Featured) -
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Forma Therapeutics, Inc.
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals
- Transgene SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Lymphoma Therapeutics
What is the estimated value of the Global Market for Lymphoma Therapeutics?
The Global Market for Lymphoma Therapeutics was estimated to be valued at $14.9 Billion in 2022.
What is the growth rate of the Global Market for Lymphoma Therapeutics?
The growth rate of the Global Market for Lymphoma Therapeutics is 6.8%, with an estimated value of $25.2 Billion by 2030.
What is the forecasted size of the Global Market for Lymphoma Therapeutics?
The Global Market for Lymphoma Therapeutics is estimated to be worth $25.2 Billion by 2030.
Who are the key companies in the Global Market for Lymphoma Therapeutics?
Key companies in the Global Market for Lymphoma Therapeutics include Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol, Myers Squibb Company, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company and F. Hoffmann.
| Report Attribute | Details |
|---|---|
| No. of Pages | 406 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 14.9 Billion |
| Forecasted Market Value ( USD | $ 25.2 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Lymphoma Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Cancer Evolves Into the Global Epidemic
- Global New Cancer Incidence (In Million) for the Year 2020
- COVID-19 Extends a Major Setback to the World’s Battle Against Cancer
- Lymphoma: Disease Causes, Risks, Types, Symptoms, Diagnosis & Survival
- New Cases of Leukemia, Lymphoma and Myeloma in the U.S. for the Year 2020
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
3. MARKET TRENDS & DRIVERS
- Targeted Therapies Grow in Popularity for Treating Lymphoma
- CT Imaging: The Gold Standard & Workhorse of Lymphoma Diagnoses & Monitoring
- 'Liquid Biopsy' Rises in Prominence Among All Other Types of Lymph Node Biopsies
- Advancements in the Field of Genomics Brings Hope for the Development of More Potent Cancer
- What Are the Approved Drugs for Lymphoma?
- Artificial Intelligence Helps Speed Up & Automate Lymphoma Diagnosis
- Global Market for AI in Healthcare (US$ Billion) for Years 2020, 2022 & 2024
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Hodgkin Lymphoma (HL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Hodgkin Lymphoma (HL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Non-Hodgkin Lymphoma (NHL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Non-Hodgkin Lymphoma (NHL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Revlimid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Revlimid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Rituxan / MabThera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Rituxan / MabThera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Imbruvica by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 18: World 18-Year Perspective for Imbruvica by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Keytruda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 21: World 18-Year Perspective for Keytruda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Adcetris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 24: World 18-Year Perspective for Adcetris by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 27: World 18-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 28: World Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: USA 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: USA 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Canada 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Canada 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
JAPAN
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: Japan 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: Japan 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
CHINA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: China 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: China 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
EUROPE
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Europe 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
FRANCE
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: France 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: France 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
GERMANY
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Germany 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Germany 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: Italy 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: Italy 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: UK 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: UK 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Spain 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Spain 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Russia 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Russia 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Rest of Europe 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Lymphoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Lymphoma Therapeutics by Disease Type - Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 109: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) for the Years 2012, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Lymphoma Therapeutics by Drug - Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 112: Asia-Pacific 18-Year Perspective for Lymphoma Therapeutics by Drug - Percentage Breakdown of Value Sales for Revlimid, Rituxan / MabThera, Imbruvica, Keytruda, Adcetris and Other Drugs for the Years 2012, 2023 & 2030
AUSTRALIA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Forma Therapeutics, Inc.
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals
- Transgene SA
